U.S. EPA’s Toxicity Reference Database: Martin and Dix Respond by Martin, Matthew T. & Dix, David J.
Perspectives | Correspondence
A 432  v o l u m e  117 | n u m b e r  10 | October 2009  •  Environmental Health Perspectives
Concerns of CropLife America 
Regarding the Application and 
Use of the U.S. EPA’s Toxicity 
Reference Database 
doi:10.1289/ehp.0900951
In a recent article in EHP, Martin et al. 
(2009) reported classifying the relative 
toxicity of chemicals using the U.S. EPA’s 
(U.S. Environmental Protection Agency) 
Toxicity Reference Database (ToxRefDB). 
The authors profiled results from in vivo 
chronic toxicity/carcinogenicity studies 
across 310 chemicals currently contained 
within ToxRefDB. This database has been 
suggested to be a model for development of 
predictive signatures of toxicity and for vali-
dation of the U.S. EPA’s ToxCast research 
program (Martin et al. 2009). Although the 
goals of the U.S. EPA program are worthy 
of our support because they promote both 
the prediction of response for chemicals 
with unknown activity and the avoidance 
of unnecessary testing in animals, CropLife 
America has several concerns regarding 
the application and use of ToxRefDB, as 
described by Martin et al.
First, we at CropLife America under-
stand that ToxRefDB is not intended for 
risk assessment purposes. However, in their 
Table 3, Martin et al. (2009) present a list of 
109 chemical compounds according to a “rel-
ative potency” grading system (using a scale 
based on lowest-effect dose levels/end points 
from chronic toxicity studies) and whether or 
not tumors occurred according to multigen-
ders/multisites/multispecies. Thus, the sum-
mary presented in Table 3 represents a hazard 
ranking system based on relative potency. 
Such systems are used as tools by some reg-
ulatory bodies to make decisions (e.g., the 
European Union, the State of California 
under Proposition 65). As a result, it is pos-
sible, and even likely, that the data in Table 3 
could be used to support regulatory action 
based solely on this relative potency ranking, 
which is outside the context of the formal 
risk assessment process. Even a cursory review 
of the chemicals listed in Table 3 reveals the 
presence of many currently registered food-
use pesticides that have not been found to 
pose any unacceptable cancer risk. Therefore, 
additional care should be taken in the future 
with regard to any potential rankings using 
ToxRefDB analyses. 
Second, it is problematic that some 
data entries for chemicals listed in Table 3 
(Martin et al. 2009) demonstrate an absence 
of available information. For example, 
we checked the accuracy of the Table 3 
entry of “N” indicating “not assessed (no 
study available).” This entry appeared for 
12 chemicals (pesticides) that denoted a 
lack of multi  species carcinogenicity data. 
In six cases (i.e., pyraclostrobin, dichlorvos, 
alachlor, captan, maneb, and propargite) 
the U.S. EPA website of Reregistration 
Eligibility Decision (RED) documents 
(U.S. EPA 2009) indicates that, contrary 
to information presented in Martin et al.’s 
Table 3, multi  species carcinogenicity studies 
are available. This inconsistency involving 
readily available information from RED 
documents and from data evaluation records 
(DERs; used primarily by the ToxRefDB) 
should be addressed to ensure future con-
sistency and completeness of the data. This 
additional check of existing information by 
the ToxRefDB is especially important given 
the statement by Martin et al. (2009) in 
their abstract that “these data are now acces-
sible and mineable within ToxRefDB and 
are serving as a primary source of validation 
for U.S. EPA’s ToxCast research program in 
predictive toxicology.” Any validation work 
performed with an incomplete database 
would be questionable.
Third, we would prefer greater transpar-
ency when analyzing “cancer datasets” involv-
ing grouping of non  neoplastic proliferative 
lesions with pre  neoplastic lesions/neoplastic 
lesions. Because this type of grouping of non-
neoplastic proliferative lesions with neoplasia 
is not standard evaluation practice (Williams 
et al. 2008), we at Crop Life America would 
prefer future ToxRefDB interpretation to 
identify specific terminology used with regard 
to scoring system(s) of end point progres-
sion schema [such as used by Martin et al. 
(2009) in their Figure 3A]. Identification 
of specific terminology and key events for 
non  neoplastic proliferative lesions and pre-
neoplastic lesions would increase transpar-
ency for future publications. Martin et al. 
stated in their “Results” that they used their 
method to increase species concordance, 
which in turn, probably increased the relative 
power of the statistical analysis. However, it 
is well known that hyperplastic lesions, for 
instance, do not always progress to tumors 
(Klaunig and Kamendulis 2007). By group-
ing non  neoplastic proliferative lesions with 
neo  plasia, Martin et al. may have increased 
species concordance and statistical power but 
may have failed to fully consider the biologi-
cal plausibility and/or consequences of the 
grouping. Moreover, the use of this contro-
versial application in the interpretation of the 
analyses presented by Martin et al. casts some 
doubt on their validity.
Finally, our last concern involves imple-
mentation of results from in vivo test-
ing, which Martin et al. (2009) compared 
with results of in vitro testing. The authors 
failed to discuss the issue of chemical activa-
tion and detoxification. It is a general prin-
ciple of toxicology that toxicity of chemicals 
can be directly dependent on metabolism 
(Kemper et al. 2008). Metabolic pathways 
exist in intact animals but not in isolated cells. 
Therefore, both pharmaco  kinetics and metab-
olism are important biological components 
of the toxicity profile of any chemical. It is 
not clear that the current analyses using the 
ToxRefDB (Martin et al. 2009) took this into 
consideration.
In conclusion, based on our four con-
cerns given above, we hope that the authors 
will address these points to increase the 
degree of clarity and consistency of interpre-
tation of analyses using the ToxRefDB. 
E.J. is employed by a trade association whose 
members manufacture and use chemicals in 
ToxRefDB.
Erik Janus
Science & Regulatory Affairs
CropLife America 
Washington, DC
E-mail: EJanus@croplifeamerica.org
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We appreciate the letter from Janus of 
CropLife America commenting on that 
group’s assessment of the database and our 
article (Martin et al. 2009a) from its perspec-
tive as an agriculture and pest-management 
trade organization. We also appreciate the 
CropLife America’s continued interest in the 
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U.S. EPA’s (U.S. Environmental Protection 
Agency) ToxRefDB and ToxCast research 
programs, including the review of much of 
the data entered into ToxRefDB. However, 
Janus’s comments do not address the 
ToxRefDB applications presented in our arti-
cle, but instead create hypothetical uses of the 
database and reported data.
For example, in Table 3 of our article 
(Martin et al. 2009a), we presented multi-
gender, multi  site, and multispecies rodent 
tumorigens in order to provide data in a sys-
tematic and computable format for predictive 
toxicity models incorporating potency values. 
In contrast, Janus and CropLife America refer 
to a hypothetical regulatory application of 
this same animal tumorigenicity data in a 
ranking system never suggested in our article. 
The U.S. EPA has gone to great lengths 
to make ToxRefDB and its development as 
transparent as possible. Three manuscripts 
and data sets have been published to date 
(Knudsen et al. 2009; Martin et al. 2009a, 
2009b), and the standardized vocabulary and 
a version of the database are available on the 
ToxRefDB website (U.S. EPA 2008b). We 
will continue to make every effort to publicly 
release information from ToxRefDB as it 
continues to develop.
We recognize the complexity of patho-
logic progression to cancer. The end point 
progression scheme we presented (Martin 
et al. 2009a) included aggregation of 
prolifera  tive, pre  neoplastic, and neo  plastic 
lesions for the development of predictive 
signatures from in vitro data coming from 
the ToxCast research program (U.S. EPA 
2008a). This approach is not controversial in 
the context of predictive toxicology research 
and is supported by the literature (Cohen 
and Arnold 2008; Hanahan and Weinberg 
2000). 
We agree that it is important to incor-
porate pharmacokinetics and metabolism, 
including chemical detoxification and acti-
vation, into predictive toxicology efforts. 
However, this issue is outside the scope of 
our article (Martin et al. 2009a) and is being 
addressed in other aspects of the ToxCast 
research program. 
Two additional papers on multi  genera-
tional reproductive and prenatal develop-
mental toxicity studies in ToxRefDB have 
been recently published (Knudsen et al. 2009; 
Martin et al. 2009b), again with the pri-
mary goal of providing diverse end points for 
predictive modeling as part of the ToxCast 
research program (Dix et al. 2007). Of toxic-
ity end points in ToxRefDB, we are using 
only those of sufficient quality for predictive 
modeling, and we are taking care to distin-
guish between missing versus negative data.
We view ToxRefDB as a valuable 
resource to the scientific community and one 
in which the U.S. EPA, stakeholders, and 
other interested parties can work together 
to ensure the success of ToxRefDB and the 
larger ToxCast effort.
The authors declare they have no competing 
financial interests.
Matthew T. Martin
David J. Dix
National Center for Computational 
Toxicology
Office of Research & Development
U.S. Environmental Protection Agency
Research Triangle Park, North Carolina
E-mail: Martin.Matt@epamail.epa.gov
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We were very interested to read the article 
by Schmidt (2009) about the increasing 
number of nano  materials and their potential 
effects. We were especially interested in the 
similarities between carbon nano  tubes and 
chrysotile asbestos fibers. The widespread use 
of asbestos-like substances with similar puta-
tive carcinogenic potential could result in 
the development of other unexpected types 
of cancer.  
The potential carcinogenic risk of nano-
materials that are structurally similar to 
asbestos and have been used in many indus-
trial fields in the last few years has been 
highlighted by Carter (2008). Some studies 
conducted in animal models suggest that 
nano  materials cause free radical–mediated 
cellular DNA damage and consequently have 
an asbestos-like carcinogenic action (Poland 
et al. 2008). 
In addition to meso  thelioma (the typi-
cal cancer index of exposure) or lung can-
cer, asbestos can cause other types of cancer. 
On the basis of our clinical experience, we 
hypothesize that at least a portion of bile 
ducts cancers (i.e., cholangio  carcinomas) are 
caused by exposure to this known carcino-
genic agent.
From 2002 to 2008 we treated 258 patients 
with cholangiocarcinoma at our institute. Over 
the previous year, we carefully interviewed 
66 consecutive patients using a standardized 
questionnaire asking about their exposure to 
asbestos and other known risk factors linked 
to bile duct carcino  genesis (Khan et al. 2008). 
We collected each patient’s remote, recent, 
and occupational clinical history. In addition 
to the association with known risk factors for 
the onset of cholangio  carcinoma, we assessed 
occupational or household exposure to asbes-
tos in 24 patients, 10 of whom did not have 
other certain risk factors (Table 1; Brandi 
et al. 2008). 
Asbestos fibers cause cancer through 
chronic inflammation, amplifying the 
production of oxygen radicals, cytokines, 
growth factors, and pro  inflammatory factors 
responsible for both impaired antioxidant 
and control cell proliferation and apoptosis 
mechanisms in target cells (Manning et al. 
2002). In contrast with findings for pleu-
ral meso  thelioma, the association between 
exposure to asbestos and the development 
of other tumors, such as gastrointestinal and 
Table 1. Characteristics of patients. 
Tumor site
No. of 
patients
Exposure to asbestos
Possible modality 
of exposure
Certain added risk 
factorsa
Household Occupational Ingestion Inhalation Absent Present
ICC   10 7/10 4/10 7/10 4/10 6/10 4/10
Klatskin tumor 6 3/6 3/6 3/6 3/6 3/6 3/6
Ampulla of Vater 1 1/1 – 1/1 – 1/1 –
Main hepatic bile duct 1 – 1/1 – 1/1 – 1/1
GBC 6 6/6 – 6/6 – – 6/6
Abbreviations: GBC, gallbladder carcinoma; HCV, hepatitis C virus; ICC: intrahepatic cholangiocarcinoma. Data updated 
from Brandi et al. (2008). 
aHCV infection or exposure to chemical substances used in industry, sporadic contact with chemical substances used in 
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bile duct cancers, has not been univocally 
demonstrated (Gamble 1994). 
The putative increased risk of bile duct 
cancer in subjects exposed to asbestos may 
be due to different mechanisms. The asbestos 
fibers cross the alveolar barrier by inhalation 
or penetrate the gastrointestinal mucosa by 
ingestion. They then reach the inter  stitial 
environ  ment and circulatory system through 
lymphatic vessels and are finally delivered to 
all tissues, namely the liver and bile ducts 
(Miserocchi et al. 2008), where they may 
start a malignant transformation process 
(Wingren 2004). In addition, asbestos fibers 
may reach the bile ducts through the papilla 
of Vater from the intestinal lumen by retro-
grade reflux, as do bacteria, and remain in 
the gallbladder for a long time.
In the near future we may have 
to consider asbestos as another factor 
accounting for the etiopathogenesis of 
cholangio  carcinomas that may explain the 
otherwise mysterious increasing incidence 
of intra  hepatic cholangio  carcinomas in 
Western countries.
The authors declare they have no competing 
financial interests.
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In the letter by O’Brien et al. [Environ Health Perspect 117:A385–386 (2009)], the 
competing financial interest declaration was incorrect. The correct declaration is as follows:
Karen Peabody O’Brien is executive director of Advancing Green Chemistry, a not-for-profit 
organization that receives support from several private foundations (listed online at http://www.
AdvancingGreenChemistry.org/AdvancingGreenChemistry/About_Us.html) to support efforts 
to build the field of green chemistry. J.P. Myers is founder, chief executive officer, and chief sci-
entist for Environmental Health Sciences (EHS), a not-for-profit organization that receives sup-
port from several private foundations (listed online at http://www.environmentalhealthnews.org/
about.html) to support EHS’s mission to advance public understanding of environ  mental health 
sciences. John Warner is president of Warner Babcock Institute for Green Chemistry, a private 
company that applies the principles of green chemis  try in the synthesis of new materials and the 
  redesign of chemical processes.
In the letter by Wilson and Schwarzman [Environ Health Perspect 117:A386 (2009)], 
the last sentence in the first paragraph was incorrect. The corrected sentence is as 
  follows: 
We would add that public policy that accurately reflects current science—and the needs of 
the chemicals market—is instrumental to the widespread adoption of green chemistry.
EHP apologizes for the error.
In the article by La Merrill et al. [Environ Health Perspect 117:1414–1419 (2009)], the keys 
in Figure 3B and Figure 5C should have been in Figure 3C and Figure 5D, respectively. The 
corrected figures are provided below.
EHP apologizes for the errors.
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Figure 3. Diet and maternal TCDD exposure effects on body composition and fasting blood glucose. 
(A) HFD increased postnatal D2 body weights (mean ± SE; n = 27–31 at PNDs 0–26 for HFD, and n = 28 
at PND35 for LFD). (B) HFD (n = 26 mice) increased percent fat at PND35 relative to LFD (mean ± SE; 
n = 28 mice). (C) Fasting blood glucose was increased by HFD and maternal TCDD-treated (n = 5 litters) 
compared with HFD and maternal vehicle-treated (n = 6 litters) female progeny at PND36 (mean ± SE). 
Because diet, but not TCDD, changed body weight and percent body fat, these analyses were done on 
individual D2 mice, with TCDD- and vehicle-treated D2 mice pooled within diet.
*p < 0.05. #p < 0.0001.
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Figure 5. Maternal TCDD exposure and effect of diet on gene expression. Normalized message levels 
are represented as mean ± SE. (C) Induction of Ahr was increased by HFD relative to LFD (n = 11 and 
10 litters, respectively). Measurements were pooled across TCDD and DMBA groups. (D) Induction of 
Cyp1b1 by DMBA was decreased compared with vehicle in HFD-fed but not in LFD-fed D2 mice. LFD 
groups are vehicle (n = 5 litters) and DMBA (n = 5 litters); HFD groups are vehicle (n = 6 litters) and 
DMBA (n = 5 litters). 
*p < 0.05.
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In the letter by O’Brien et al. [Environ Health Perspect 117:A385–386 (2009)], the 
competing financial interest declaration was incorrect. The correct declaration is as follows:
Karen Peabody O’Brien is executive director of Advancing Green Chemistry, a not-for-profit 
organization that receives support from several private foundations (listed online at http://www.
AdvancingGreenChemistry.org/AdvancingGreenChemistry/About_Us.html) to support efforts 
to build the field of green chemistry. J.P. Myers is founder, chief executive officer, and chief sci-
entist for Environmental Health Sciences (EHS), a not-for-profit organization that receives sup-
port from several private foundations (listed online at http://www.environmentalhealthnews.org/
about.html) to support EHS’s mission to advance public understanding of environ  mental health 
sciences. John Warner is president of Warner Babcock Institute for Green Chemistry, a private 
company that applies the principles of green chemis  try in the synthesis of new materials and the 
  redesign of chemical processes.
In the letter by Wilson and Schwarzman [Environ Health Perspect 117:A386 (2009)], 
the last sentence in the first paragraph was incorrect. The corrected sentence is as 
  follows: 
We would add that public policy that accurately reflects current science—and the needs of 
the chemicals market—is instrumental to the widespread adoption of green chemistry.
EHP apologizes for the error.
In the article by La Merrill et al. [Environ Health Perspect 117:1414–1419 (2009)], the keys 
in Figure 3B and Figure 5C should have been in Figure 3C and Figure 5D, respectively. The 
corrected figures are provided below.
EHP apologizes for the errors.
In the article by Alyea and Watson [Environ Health Perspect 117:778–783 (2009)], the x-axis labels in Figure 2 were incorrect. 
The corrected figure appears below. 
EHP apologizes for the error.
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Figure 2. Concentration-dependent dopamine efflux patterns for E2 and XEs 
at 9 (A) and 5 min (B), using optimal time points for each compound chosen 
from the 10–9 M time course (Figure 1). (A) A 9-min dopamine efflux for E2, 
DES, endosulfan, DDE, NP, and BPA at concentrations ranging from 10–14 to 
10–9 M. (B) A 5-min dopamine efflux for E2, dieldrin, NP, and BPA at concen-
trations ranging from 10–14 to 10–9 M. Values are means and SEs; numbers 
per treatment are as follows: E2, n = 18; dieldrin, n = 12; DES, n = 18; endosul-
fan, n = 12; DDE, n = 12; BPA, n = 23; NP, n = 15. Points above the zero point 
line indicate a positive efflux of dopamine from the cells. 
*p < 0.05 compared with control. #p < 0.05 compared with E2 treatment. 